Delving into the Latest Updates on Lascufloxacin Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

KRP-AM1977, LSFX, Lascufloxacin

+ [8]

Target

Bacterial DNA gyrase x Bacterial top IV

Mechanism

Bacterial DNA gyrase inhibitors, Bacterial top IV inhibitors(Bacterial topoisomerase IV inhibitors)

Therapeutic Areas

Infectious DiseasesRespiratory DiseasesOther Diseases

Active Indication

Lung AbscessPneumoniaLower Respiratory Tract Infections

Inactive Indication-

Originator Organization

KYORIN Pharmaceutical Co., Ltd.

Active Organization

KYORIN Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (27 Nov 2020),

Lung AbscessPneumonia

Regulation-

Login to view timeline

Structure

Molecular FormulaC21H24F3N3O4

InChIKeyZFIOCUITTUUVPV-MEDUHNTESA-N

CAS Registry848416-07-9

Human metapneumovirus (hMPV) is a respiratory pathogen that can cause lower respiratory tract infections and pneumonia in immunocompetent adults. Pneumonia caused by hMPV is reportedly more likely to cause bronchial wall thickening and ground-glass opacity (GGO). A 44-year-old woman with no significant medical history developed fever, cough, and nausea. Computed tomography of the chest showed scattered GGOs in the right upper lobe and infiltrating shadows with air bronchograms in the left lingual and bilateral lower lobes. The patient was admitted to our hospital for further evaluation. Atypical pneumonia was suspected and lascufloxacin (LSFX) was started. Multiplex polymerase chain reaction (PCR) detected hMPV on hospital day 2 using the FilmArray Respiratory Panel 2.1. Pneumonia due to hMPV was suspected and LSFX was discontinued. The patient subsequently showed spontaneous improvement and was discharged on hospital day 6 after admission. After discharge, pneumonia continued to improve. Early detection of respiratory pathogens using multiplex PCR can help determine the appropriate treatment strategy. As hMPV can also cause lobar pneumonia, we should consider pneumonia due to hMPV in the differential diagnosis of lobar pneumonia.

01 Jul 2024·Journal of Infection and Chemotherapy

Efficacy and safety of lascufloxacin for nursing- and healthcare-associated pneumonia: A single-arm, open-label clinical trial

Article

Author: Fukushima, Kiyoyasu ; Kondo, Akira ; Fukuda, Yuichi ; Inoue, Yuichi ; Ide, Shotaro ; Iwanaga, Naoki ; Imamura, Yoshifumi ; Irifune, Satoshi ; Hanaka, Tetsuya ; Suyama, Naofumi ; Ito, Yuya ; Yanagihara, Katsunori ; Tanaka, Hikaru ; Mihara, Tomo ; Sasaki, Eisuke ; Harada, Yosuke ; Takeda, Kazuaki ; Morikawa, Toru ; Sawai, Toyomitsu ; Nakada, Nana ; Yatera, Kazuhiro ; Shimabukuro, Ikuko ; Funada, Midori ; Yoshida, Masataka ; Hata, Ryosuke ; Futsuki, Yoji ; Morio, Ryosuke ; Fukushima, Koki ; Izumikawa, Koichi ; Morimoto, Shimpei ; Hosogaya, Naoki ; Ota, Kenji ; Nemoto, Kazuki ; Nagayoshi, Yosuke ; Mukae, Hiroshi ; Miyamura, Takuto ; Takazono, Takahiro

BACKGROUNDNursing- and healthcare-associated pneumonia (NHCAP) constitutes most of the pneumonia in elderly patients including aspiration pneumonia in Japan. Lascufloxacin (LSFX) possesses broad antibacterial activity against respiratory pathogens, such as Streptococcus spp. And anaerobes inside the oral cavity. However, the efficacy and safety of LSFX in NHCAP treatment remains unknown. We aimed to evaluate the efficacy and safety of LSFX tablets in the treatment of patients with NHCAP.METHODSIn this single-arm, open-label, uncontrolled study, LSFX was administered to patients with NHCAP at 24 facilities. The study participants were orally administered 75 mg LSFX once daily for 7 days. The primary endpoint was the clinical efficacy at the time of test of cure (TOC). The secondary endpoints included clinical efficacy at the time of end of treatment (EOT), early clinical efficacy, microbiological efficacy, and safety analysis.RESULTDuring the study period, 75 patients provided written informed consent to participate and were included. Finally, 56 and 71 patients were eligible for clinical efficacy and safety analyses, respectively. The median age of the patients was significantly high at 86 years. All patients were classified as having moderate disease severity using the A-DROP scoring system. LSFX tablets demonstrated high efficacy rates of 78.6 % at TOC and 89.3 % at EOT. The risk factors for resistant bacteria or aspiration pneumonia did not affect clinical efficacy. No severe adverse events associated with the study drugs were observed.CONCLUSIONOral LSFX is an acceptable treatment option for moderate NHCAP in elderly patients who can take oral medications.

01 Jul 2024·Journal of Infection and Chemotherapy

Temporal effects of lascufloxacin on human gut and salivary microbiota: Analysis using next-generation sequencing method

Article

Author: Endo, Yusuke ; Morishima, So ; Oda, Machi ; Mukuda, Kengo ; Doi, Ayumu ; Inoue, Ryo ; Nishikawa, Yukari ; Ma'arif, Athok Shofiudin ; Chikumi, Hiroki ; Noma, Hisashi ; Sunada, Hiroshi ; Matsuda, Risa ; Okada, Kensaku ; Nakamoto, Masaki ; Kitaura, Tsuyoshi ; Takata, Miyako ; Yamasaki, Akira ; Takazawa, Kenji

INTRODUCTIONAntimicrobial treatment disrupts human microbiota. The effects of lascufloxacin (LSFX), a new fluoroquinolone, on human microbiota remains unknown. Therefore, in this study, we aimed to evaluate the effects of LSFX administration on the gut and salivary microbiota of healthy participants and those with pneumonia.METHODSLSFX (75 mg, once a day, orally) was administered to healthy adults (healthy group) and adult patients with pneumonia (pneumonia group), and fecal and saliva samples were collected at five time points (Days 0, 3, 7, 14, and 28). Using the collected samples, α- and β-diversity indices, as well as bacterial composition of the gut microbiota and salivary microbiota were analyzed using next-generation sequencing.RESULTSIn the healthy group, α-diversity indices of the gut and salivary microbiota were reduced and the lowest values on Day 3. For the gut microbiota, the Chao1 index (richness) recovered on Day 28, whereas the Shannon index (evenness) did not. In the salivary microbiota, the Chao1 and Shannon indices did not recover within the 28 day period. The β-diversity indices changed after LSFX administration and subsequently recovered on Day 28. After LSFX administration, the abundance of the Lachnospiraceae family decreased in the gut microbiota, and the abundance of Granulicatella, Streptococcus, Prevotella, Absconditabacteriales(SR1), and Saccharimonadales decreased in the salivary microbiota. In the pneumonia group, the α-diversity indices were lowest on Day 14 after LSFX administration.CONCLUSIONSWe elucidated that LSFX administration differentially affected the gut and salivary microbiota; however, the richness and beta diversity recovered within 28 days.

1

News (Medical) associated with Lascufloxacin Hydrochloride

27 Sep 2019

·www.bioportfolio.com

Pipeline Watch: Roxadustat, Lascufloxacin Approvals In Japan

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical... Related Stories Genmab Cash Pile To Grow With Another Darzalex OK Jazz Poised To Hold Onto Strong Sleep Disorder Position Novartis Bemused As NICE Says No Again To Migraine Drug Aimovig

100 Deals associated with Lascufloxacin Hydrochloride

Login to view more data